CHMP positive opinion on Pomalidomide

Access, MyelomaLeave a comment

The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Pomalidomide (Pomalidomide Celgene®) in the treatment of multiple myeloma for relapsed and refractory myeloma patients. The next step is for the European Commission to adopt the final licensing decision within three months. There is no doubt that this is a crucial step for patients within the EU…

II Masterclass on personalized medicine in multiple myeloma

MyelomaLeave a comment

Madrid, Saturday 13 April 2013 (9:00am – 4:30pm)   After the success of MPe’s I Masterclass that took place in Edinburgh last year, the second one will follow this spring focusing on myeloma genetics and the role of bio banks. The issue will be presented and discussed from a medical point of view, but also from the patient perspective, particularly concerning the ethical issues involved in these kind of treatments.